New biotech Roxiant to tackle age-related diseases

Pharmacosmos heir Andreas Christensen, who recently founded the biotech company Roxiant, will use a protein found in people who live for an exceptionally long time to treat age-related diseases, and its first target is Huntington's disease.

Andreas Christensen has left his family's company Pharmacosmos to become CEO in the biotech business Roxiant. | Photo: Roxiant / PR

Andreas Christensen flew the nest last year, leaving Pharmacosmos, which was founded by his paternal grandfather Henry Christensen and is still run by the family, to start biotech firm Roxiant.

He still has prominent backing, however, in the form of ALK boss Rasmus Just, who is chair of the board of Roxiant, and Kasper Gubba Ørtenblad, who is a familiar face in Danish biotech. He has taken on the role of director of operations, and a handful of other medtech and pharma players are joining the team.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs